{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:01:14Z","timestamp":1788861674999,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cushing\u2019s syndrome is known as an important cause of secondary osteoporosis, characterized by reduction of bone mineral density and potential occurrence of fragility fractures before diagnosis in young population. Therefore, for young patients with fragility fractures, especially in young women, more attention should be paid on glucocorticoid excess caused by Cushing\u2019s syndrome, due to relatively higher rate of misdiagnosis, distinct pathological characteristics and different treatment strategies compared with violent fractures and primary osteoporosis related fractures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We presented an unusual case of a 26-year-old woman with multiple vertebral compression fractures and pelvis fractures, subsequently diagnosed as Cushing\u2019s syndrome. On admission, the radiographic results showed fresh second lumbar vertebra fracture, and old fourth lumbar vertebra and pelvic fractures. The dual energy X-ray absorptiometry of lumbar spine revealed marked osteoporosis, and her plasm cortisol was extremely high. Then, Cushing\u2019s syndrome, caused by left adrenal adenoma, was diagnosed by further endocrinological and radiographic examinations. After receiving left adrenalectomy, her plasma ACTH and cortisol values returned to normal level. In term of OVCF, we adopted conservative treatments, including pain management, brace treatment, and anti-osteoporosis measures. Three months after discharge, the patient\u2019s low back pain was in complete remission without new onset of pain, and returned to normal life and work. Furthermore, we reviewed the literatures on advancements in the treatment of OVCF caused by Cushing\u2019s syndrome, and based on our experiences, proposed some additional perspectives to guide treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In term of OVCF secondary to Cushing\u2019s syndrome without neurological damage, we prefer systematic conservative treatments, including pain management, brace treatment, and anti-osteoporosis measures, to surgical treatment. Among them, anti-osteoporosis treatment has the highest priority because of the reversibility of osteoporosis caused by Cushing\u2019s syndrome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-023-06253-9","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T07:05:07Z","timestamp":1678086307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Osteoporotic vertebral compression fractures caused by Cushing\u2019s syndrome in young women: case report and literature review"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0452-2266","authenticated-orcid":false,"given":"Jie","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songli","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"6253_CR1","unstructured":"Bouxsein M, Genant H (2010). International osteoporosis foundation vertebral fracture audit. www.iofbonehealth.org."},{"issue":"7","key":"6253_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611\u201329. https:\/\/doi.org\/10.1016\/S2213-8587(16)00086-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"6253_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1113\/jphysiol.2014.282871","volume":"593","author":"H Raff","year":"2015","unstructured":"Raff H, Carroll T. Cushing's syndrome: from physiological principles to diagnosis and clinical care. J Physiol. 2015;593(3):493\u2013506. https:\/\/doi.org\/10.1113\/jphysiol.2014.282871.","journal-title":"J Physiol"},{"issue":"9996","key":"6253_CR4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A, Feelders RA, Stratakis CA, et al. Cushing's syndrome. Lancet. 2015;386(9996):913\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(14)61375-1.","journal-title":"Lancet"},{"issue":"1","key":"6253_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1210\/jcem.86.1.7093","volume":"86","author":"J Lindholm","year":"2001","unstructured":"Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117\u201323. https:\/\/doi.org\/10.1210\/jcem.86.1.7093.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"6253_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1530\/EJE-15-0189","volume":"173","author":"TT Agustsson","year":"2015","unstructured":"Agustsson TT, Baldvinsdottir T, Jonasson JG, et al. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur J Endocrinol. 2015;173(5):655\u201364. https:\/\/doi.org\/10.1530\/EJE-15-0189.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"6253_CR7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1365-2265.2011.04124.x","volume":"75","author":"MJ Bolland","year":"2011","unstructured":"Bolland MJ, Holdaway IM, Berkeley JE, et al. Mortality and morbidity in Cushing's syndrome in New Zealand. Clin Endocrinol. 2011;75(4):436\u201342. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04124.x.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"6253_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1530\/EJE-11-0272","volume":"165","author":"E Valassi","year":"2011","unstructured":"Valassi E, Santos A, Yaneva M, et al. The European registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011;165(3):383\u201392. https:\/\/doi.org\/10.1530\/EJE-11-0272.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"6253_CR9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/cen.12812","volume":"83","author":"CV dos Santos","year":"2015","unstructured":"dos Santos CV, Vieira Neto L, Madeira M, et al. Bone density and microarchitecture in endogenous hypercortisolism. Clin Endocrinol. 2015;83(4):468\u201374. https:\/\/doi.org\/10.1111\/cen.12812.","journal-title":"Clin Endocrinol"},{"issue":"5","key":"6253_CR10","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1210\/jc.2005-0582","volume":"91","author":"L Tauchmanova","year":"2006","unstructured":"Tauchmanova L, Pivonello R, Di Somma C, et al. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab. 2006;91(5):1779\u201384. https:\/\/doi.org\/10.1210\/jc.2005-0582.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6253_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00198-013-2520-5","volume":"25","author":"L Trementino","year":"2014","unstructured":"Trementino L, Appolloni G, Ceccoli L, et al. Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants. Osteoporos Int. 2014;25(3):913\u201321. https:\/\/doi.org\/10.1007\/s00198-013-2520-5.","journal-title":"Osteoporos Int"},{"issue":"1","key":"6253_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1507\/endocrj.50.1","volume":"50","author":"N Ohmori","year":"2003","unstructured":"Ohmori N, Nomura K, Ohmori K, et al. Osteoporosis is more prevalent in adrenal than in pituitary Cushing's syndrome. Endocr J. 2003;50(1):1\u20137. https:\/\/doi.org\/10.1507\/endocrj.50.1.","journal-title":"Endocr J"},{"key":"6253_CR13","doi-asserted-by":"publisher","unstructured":"Ferriere A, Tabarin A (2020) Cushing's syndrome: treatment and new therapeutic approaches. Best Pract Res Clin Endocrinol Metab 34(2):101381. https:\/\/doi.org\/10.1016\/j.beem.2020.101381.","DOI":"10.1016\/j.beem.2020.101381"},{"key":"6253_CR14","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3389\/fendo.2020.00648","volume":"11","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Ferrigno R, De Martino MC, et al. Medical treatment of Cushing's disease: an overview of the current and recent clinical trials. Front Endocrinol (Lausanne). 2020;11:648. https:\/\/doi.org\/10.3389\/fendo.2020.00648.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9746","key":"6253_CR15","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(10)60954-3","volume":"376","author":"CA Klazen","year":"2010","unstructured":"Klazen CA, Lohle PN, de Vries J, et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. Lancet. 2010;376(9746):1085\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(10)60954-3.","journal-title":"Lancet"},{"issue":"10052","key":"6253_CR16","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/S0140-6736(16)31341-1","volume":"388","author":"W Clark","year":"2016","unstructured":"Clark W, Bird P, Gonski P, et al. Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;388(10052):1408\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(16)31341-1.","journal-title":"Lancet"},{"issue":"12","key":"6253_CR17","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s00270-017-1779-x","volume":"40","author":"DK Filippiadis","year":"2017","unstructured":"Filippiadis DK, Marcia S, Masala S, et al. Percutaneous Vertebroplasty and Kyphoplasty: current status, new developments and old controversies. Cardiovasc Intervent Radiol. 2017;40(12):1815\u201323. https:\/\/doi.org\/10.1007\/s00270-017-1779-x.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"6253_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4103\/0256-4947.81542","volume":"31","author":"NA Al-Nakshabandi","year":"2011","unstructured":"Al-Nakshabandi NA. Percutaneous vertebroplasty complications. Ann Saudi Med. 2011;31(3):294\u20137. https:\/\/doi.org\/10.4103\/0256-4947.81542.","journal-title":"Ann Saudi Med"},{"issue":"5","key":"6253_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3171\/2010.12.SPINE10286","volume":"14","author":"MR Farrokhi","year":"2011","unstructured":"Farrokhi MR, Alibai E, Maghami Z. Randomized controlled trial of percutaneous vertebroplasty versus optimal medical management for the relief of pain and disability in acute osteoporotic vertebral compression fractures. J Neurosurg Spine. 2011;14(5):561\u20139. https:\/\/doi.org\/10.3171\/2010.12.SPINE10286.","journal-title":"J Neurosurg Spine"},{"issue":"4","key":"6253_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/BSD.0b013e31823f6298","volume":"26","author":"CH Su","year":"2013","unstructured":"Su CH, Tu PH, Yang TC, et al. Comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty. J Spinal Disord Tech. 2013;26(4):200\u20136. https:\/\/doi.org\/10.1097\/BSD.0b013e31823f6298.","journal-title":"J Spinal Disord Tech"},{"issue":"9","key":"6253_CR21","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00264-018-3838-6","volume":"42","author":"YX Li","year":"2018","unstructured":"Li YX, Guo DQ, Zhang SC, et al. Risk factor analysis for re-collapse of cemented vertebrae after percutaneous vertebroplasty (PVP) or percutaneous kyphoplasty (PKP). Int Orthop. 2018;42(9):2131\u20139. https:\/\/doi.org\/10.1007\/s00264-018-3838-6.","journal-title":"Int Orthop"},{"key":"6253_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2147\/CIA.S312623","volume":"16","author":"ZL Zhang","year":"2021","unstructured":"Zhang ZL, Yang JS, Hao DJ, et al. Risk factors for new vertebral fracture after percutaneous Vertebroplasty for osteoporotic vertebral compression fractures. Clin Interv Aging. 2021;16:1193\u2013200. https:\/\/doi.org\/10.2147\/CIA.S312623.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"6253_CR23","first-page":"E12","volume":"20","author":"H Zhang","year":"2017","unstructured":"Zhang H, Xu C, Zhang T, et al. Does percutaneous vertebroplasty or balloon kyphoplasty for osteoporotic vertebral compression fractures increase the incidence of new vertebral fractures? A meta-analysis. Pain Physician. 2017;20(1):E12\u201328.","journal-title":"Pain Physician"},{"issue":"1","key":"6253_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1186\/s13018-021-02722-w","volume":"16","author":"W Mao","year":"2021","unstructured":"Mao W, Dong F, Huang G, et al. Risk factors for secondary fractures to percutaneous vertebroplasty for osteoporotic vertebral compression fractures: a systematic review. J Orthop Surg Res. 2021;16(1):644. https:\/\/doi.org\/10.1186\/s13018-021-02722-w.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"6253_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13018-022-03038-z","volume":"17","author":"C Dai","year":"2022","unstructured":"Dai C, Liang G, Zhang Y, et al. Risk factors of vertebral re-fracture after PVP or PKP for osteoporotic vertebral compression fractures, especially in eastern Asia: a systematic review and meta-analysis. J Orthop Surg Res. 2022;17(1):161. https:\/\/doi.org\/10.1186\/s13018-022-03038-z.","journal-title":"J Orthop Surg Res"},{"issue":"6","key":"6253_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1056\/NEJMoa0900429","volume":"361","author":"R Buchbinder","year":"2009","unstructured":"Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med. 2009;361(6):557\u201368. https:\/\/doi.org\/10.1056\/NEJMoa0900429.","journal-title":"N Engl J Med"},{"key":"6253_CR27","doi-asserted-by":"publisher","first-page":"k1551","DOI":"10.1136\/bmj.k1551","volume":"361","author":"CE Firanescu","year":"2018","unstructured":"Firanescu CE, de Vries J, Lodder P, et al. Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial. BMJ. 2018;361:k1551. https:\/\/doi.org\/10.1136\/bmj.k1551.","journal-title":"BMJ"},{"key":"6253_CR28","doi-asserted-by":"publisher","unstructured":"Buchbinder R, Johnston RV, Rischin KJ, et al. Percutaneous vertebroplasty for osteoporotic vertebral compression fracture. Cochrane Database Syst Rev. 2018;4(4):CD006349. https:\/\/doi.org\/10.1002\/14651858.CD006349.pub3.","DOI":"10.1002\/14651858.CD006349.pub3"},{"issue":"2","key":"6253_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11102-011-0306-3","volume":"15","author":"ME Randazzo","year":"2012","unstructured":"Randazzo ME, Grossrubatscher E, Dalino Ciaramella P, et al. Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary. 2012;15(2):193\u2013201. https:\/\/doi.org\/10.1007\/s11102-011-0306-3.","journal-title":"Pituitary"},{"issue":"5","key":"6253_CR30","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s00268-007-9394-7","volume":"32","author":"A Kawamata","year":"2008","unstructured":"Kawamata A, Iihara M, Okamoto T, et al. Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: prospective study. World J Surg. 2008;32(5):890\u20136. https:\/\/doi.org\/10.1007\/s00268-007-9394-7.","journal-title":"World J Surg"},{"key":"6253_CR31","doi-asserted-by":"publisher","first-page":"CD000333","DOI":"10.1002\/14651858.CD000333.pub2","volume":"7","author":"TE Howe","year":"2011","unstructured":"Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011;7:CD000333. https:\/\/doi.org\/10.1002\/14651858.CD000333.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"6253_CR32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00198-015-3290-z","volume":"27","author":"MH Thorin","year":"2016","unstructured":"Thorin MH, Wihlborg A, Akesson K, et al. Smoking, smoking cessation, and fracture risk in elderly women followed for 10 years. Osteoporos Int. 2016;27(1):249\u201355. https:\/\/doi.org\/10.1007\/s00198-015-3290-z.","journal-title":"Osteoporos Int"},{"issue":"5","key":"6253_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00223-020-00744-w","volume":"107","author":"W Kemmler","year":"2020","unstructured":"Kemmler W, Shojaa M, Kohl M, et al. Effects of different types of exercise on bone mineral density in postmenopausal women: a systematic review and Meta-analysis. Calcif Tissue Int. 2020;107(5):409\u201339. https:\/\/doi.org\/10.1007\/s00223-020-00744-w.","journal-title":"Calcif Tissue Int"},{"issue":"9588","key":"6253_CR34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(07)61342-7","volume":"370","author":"BM Tang","year":"2007","unstructured":"Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(07)61342-7.","journal-title":"Lancet"},{"issue":"12","key":"6253_CR35","doi-asserted-by":"publisher","first-page":"e1917789","DOI":"10.1001\/jamanetworkopen.2019.17789","volume":"2","author":"P Yao","year":"2019","unstructured":"Yao P, Bennett D, Mafham M, et al. Vitamin D and calcium for the prevention of fracture: a systematic review and Meta-analysis. JAMA Netw Open. 2019;2(12):e1917789. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.17789.","journal-title":"JAMA Netw Open"},{"key":"6253_CR36","doi-asserted-by":"publisher","first-page":"b5463","DOI":"10.1136\/bmj.b5463","volume":"340","author":"Group D","year":"2010","unstructured":"Group D. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ. 2010;340:b5463. https:\/\/doi.org\/10.1136\/bmj.b5463.","journal-title":"BMJ"},{"issue":"1","key":"6253_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","volume":"17","author":"CL Gregson","year":"2022","unstructured":"Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022;17(1):58. https:\/\/doi.org\/10.1007\/s11657-022-01061-5.","journal-title":"Arch Osteoporos"},{"issue":"10","key":"6253_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.7326\/M14-0317","volume":"161","author":"CJ Crandall","year":"2014","unstructured":"Crandall CJ, Newberry SJ, Diamant A, et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med. 2014;161(10):711\u201323. https:\/\/doi.org\/10.7326\/M14-0317.","journal-title":"Ann Intern Med"},{"issue":"9041","key":"6253_CR39","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/s0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535\u201341. https:\/\/doi.org\/10.1016\/s0140-6736(96)07088-2.","journal-title":"Lancet"},{"issue":"9","key":"6253_CR40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604\u201310. https:\/\/doi.org\/10.1056\/NEJM200008313430902.","journal-title":"N Engl J Med"},{"issue":"5","key":"6253_CR41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med. 1998;339(5):292\u20139. https:\/\/doi.org\/10.1056\/NEJM199807303390502.","journal-title":"N Engl J Med"},{"issue":"1","key":"6253_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with Risedronate therapy (VERT) study group. Osteoporos Int. 2000;11(1):83\u201391. https:\/\/doi.org\/10.1007\/s001980050010.","journal-title":"Osteoporos Int"},{"issue":"4","key":"6253_CR43","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1359\/jbmr.081214","volume":"24","author":"S Boonen","year":"2009","unstructured":"Boonen S, Orwoll ES, Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009;24(4):719\u201325. https:\/\/doi.org\/10.1359\/jbmr.081214.","journal-title":"J Bone Miner Res"},{"issue":"18","key":"6253_CR44","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799\u2013809. https:\/\/doi.org\/10.1056\/NEJMoa074941.","journal-title":"N Engl J Med"},{"issue":"10102","key":"6253_CR45","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(17)31613-6.","journal-title":"Lancet"},{"issue":"19","key":"6253_CR46","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434\u201341. https:\/\/doi.org\/10.1056\/NEJM200105103441904.","journal-title":"N Engl J Med"},{"issue":"10","key":"6253_CR47","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1210\/jcem.80.10.7559865","volume":"80","author":"AR Hermus","year":"1995","unstructured":"Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab. 1995;80(10):2859\u201365. https:\/\/doi.org\/10.1210\/jcem.80.10.7559865.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6253_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1365-2265.1992.tb01437.x","volume":"36","author":"PJ Manning","year":"1992","unstructured":"Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol. 1992;36(3):229\u201334. https:\/\/doi.org\/10.1111\/j.1365-2265.1992.tb01437.x.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"6253_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.11005\/jbm.2012.19.2.153","volume":"19","author":"JY Han","year":"2012","unstructured":"Han JY, Lee J, Kim GE, et al. A case of Cushing syndrome diagnosed by recurrent pathologic fractures in a young woman. J Bone Metab. 2012;19(2):153\u20138. https:\/\/doi.org\/10.11005\/jbm.2012.19.2.153.","journal-title":"J Bone Metab"},{"issue":"1","key":"6253_CR50","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44(1):202\u201311.\u00a0","journal-title":"Arthritis Rheum"},{"issue":"8","key":"6253_CR51","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3899\/jrheum.081207","volume":"36","author":"SA Stoch","year":"2009","unstructured":"Stoch SA, Saag KG, Greenwald M, et al. Once-weekly Oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol. 2009;36(8):1705\u201314. https:\/\/doi.org\/10.3899\/jrheum.081207.","journal-title":"J Rheumatol"},{"issue":"20","key":"6253_CR52","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028\u201339. https:\/\/doi.org\/10.1056\/NEJMoa071408.","journal-title":"N Engl J Med"},{"issue":"1","key":"6253_CR53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","volume":"61","author":"J Compston","year":"2018","unstructured":"Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61(1):7\u201316. https:\/\/doi.org\/10.1007\/s12020-018-1588-2.","journal-title":"Endocrine"},{"issue":"6","key":"6253_CR54","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00198-019-04906-x","volume":"30","author":"G Adami","year":"2019","unstructured":"Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019;30(6):1145\u201356. https:\/\/doi.org\/10.1007\/s00198-019-04906-x.","journal-title":"Osteoporos Int"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-023-06253-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-023-06253-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-023-06253-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T07:05:32Z","timestamp":1678086332000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-023-06253-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6253"],"URL":"https:\/\/doi.org\/10.1186\/s12891-023-06253-9","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board of Affiliated Hospital of Zunyi Medical University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the participant included in the study. And, all methods were carried out in accordance with relevant guidelines and regulations (declaration of Helsinki).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The participant gave written consent for their personal or clinical details along with any identifying images to be published in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}